In vitro studies on adult cardiac myocytes: Attachment and biosynthesis of collagen type IV and laminin

1988 ◽  
Vol 136 (1) ◽  
pp. 43-53 ◽  
Author(s):  
Evy Lundgren ◽  
Donald Gullberg ◽  
Kristofer Rubin ◽  
Thomas K. Borg ◽  
Marjorie J. Terracio ◽  
...  
Keyword(s):  
Cardiac Myocytes ◽  
Collagen Type ◽  
In Vitro Studies ◽  
Collagen Type Iv ◽  
Type Iv ◽  
Adult Cardiac Myocytes

Effect of everolimus on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC): Results from EXIST-1 and EXIST-2.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10619-10619
Author(s):  
David Neal Franz ◽  
Christopher Kingswood ◽  
Sergiusz Jozwiak ◽  
Klemens Budde ◽  
Elena Belousova ◽  
...  
Keyword(s):  
Growth Factor ◽  
Collagen Type ◽  
Plasma Concentrations ◽  
Collagen Type Iv ◽  
Subependymal Giant Cell Astrocytoma ◽  
Renal Angiomyolipoma ◽  
Vegf Receptor ◽  
Double Blind ◽  
Type Iv

10619 Background: The efficacy and safety of everolimus, an oral mTOR inhibitor, was assessed in two randomized, double-blind, placebo-controlled, phase 3 trials: EXIST-1 (NCT00789828) and EXIST-2 (NCT00790400). EXIST-1 examined everolimus for the treatment of subependymal giant cell astrocytoma (SEGA) associated with TSC and EXIST-2 for the treatment of renal angiomyolipoma (AML) associated with either TSC or sporadic lymphangioleiomyomatosis. In each instance, everolimus was superior to placebo for the primary endpoints, SEGA and renal AML response rates. Inhibitors of mTOR have antiangiogenic effects on tumor growth in vitro and in vivo. Methods: Patients were randomized to receive everolimus (n=78) starting at 4.5 mg/m2/day (target trough, 5-15 ng/mL) or placebo (n=39) in EXIST-1 and 10 mg/day everolimus (n=79) or placebo (n=39) in EXIST-2. Plasma samples were taken at baseline and pre-dosing on day 1 of weeks 4, 12, 24, 36, and 48 of treatment. Angiogenic markers of interest were vascular endothelial growth factor (VEGF)-A and -D, placental growth factor (PlGF), soluble VEGF receptor-1 (sVEGFR1), soluble VEGF receptor 2 (sVEGFR2), c-Kit, and collagen type IV. Results: Compared with placebo, a sustained ~30% and ~60% increase in VEGF-A was observed in the everolimus arm of EXIST-1 and EXIST-2, respectively. A concomitant decrease in collagen type IV (~25% EXIST-1; ~45% EXIST-2) and sVEGFR2 (~25% both trials) was also observed in the everolimus arm. A sustained decrease (~60%) in VEGF-D was observed in the everolimus arm of EXIST-2, but not EXIST-1. In both studies, no change was observed in PlGF, sVEGFR1, or c-Kit plasma concentrations in the everolimus arm or any biomarkers evaluated in the placebo arm. Baseline sVEGFR2 and VEGF-D were ~40% and ~4-fold higher, respectively, while VEGF-A was ~50% lower in EXIST-2 compared with EXIST-1. A similar baseline plasma concentration for the other biomarkers was noted in both studies. Conclusions: Patients presenting with SEGA or renal AML associated with TSC had a reduction in plasma concentrations of sVEGFR2, collagen type IV, and VEGF-D (AML only) and an increase in VEGF-A. Everolimus may have antiangiogenic properties in TSC patients.

scholarly journals Migration through the Extracellular Matrix by the Parasitic Protozoan Leishmania Is Enhanced by Surface Metalloprotease gp63

2003 ◽  
Vol 71 (2) ◽  
pp. 1008-1010 ◽  
Author(s):  
Bradford S. McGwire ◽  
Kwang-Poo Chang ◽  
David M. Engman
Keyword(s):  
Extracellular Matrix ◽  
Collagen Type ◽  
Collagen Type Iv ◽  
Parasitic Protozoan ◽  
Type Iv ◽  
Extracellular Matrix Components ◽  
Matrix Components

ABSTRACT Leishmania species engineered to express high levels of the surface metalloprotease gp63 have enhanced capacity of migration through extracellular matrix in vitro. This correlates with gp63 degradation of extracellular matrix components, such as collagen type IV and fibronectin, and suggests an important role for gp63 in the pathogenesis of leishmaniasis.

Effect of in vitro Glycation of Human Placental Collagen (Type IV) on Platelet Aggregation

2005 ◽  
Vol 8 (9) ◽  
pp. 1203-1206 ◽  
Author(s):  
Goodarzi Mohammad Ta . ◽  
Rezaei Mohsen . ◽  
Piry Hossein . ◽  
Amiry Saied .
Keyword(s):  
Platelet Aggregation ◽  
Collagen Type ◽  
Collagen Type Iv ◽  
Type Iv

Release of collagen type IV degrading activity from C6 astrocytoma cells and cell density

1996 ◽  
Vol 84 (6) ◽  
pp. 1013-1019 ◽  
Author(s):  
Masashi Tamaki ◽  
Warren McDonald ◽  
Rolando F. Del Maestro
Keyword(s):  
Cell Density ◽  
Collagen Type ◽  
Cell Communication ◽  
Collagen Type Iv ◽  
Major Protein ◽  
Content Type ◽  
Type Iv ◽  
Astrocytoma Cells ◽  
C6 Astrocytoma

✓ Type IV collagen is a major protein component of the vascular basement membrane and its degradation is crucial to the initiation of tumor-associated angiogenesis. The authors have investigated the influence of cell density on the release of collagen type IV degrading activity by C6 astrocytoma cells in monolayer culture. The release of collagen type IV degrading activity was assessed biochemically, immunocytochemically, and by Western blot analysis. The results demonstrate that increasing plating density and increasing cell density are associated with decreased collagen type IV degrading activity released per tumor cell. These findings indicate the existence of regulatory mechanisms dependent on cell—cell communication, which modulate release of collagen type IV degrading activity. The extrapolation of these results to the in vivo tumor microenvironment would suggest that individual and/or small groups of invading tumor cells, distant from the main tumor mass, would release substantial collagen type IV degrading activity, which may be crucial to their continued invasion and to angiogenesis.

Collagen type IV in acute rejection of kidney

2000 ◽  
Vol 32 (7) ◽  
pp. 1785 ◽  
Author(s):  
K Utsumi ◽  
T Sawada ◽  
E Adachi ◽  
S Horita ◽  
T Tojimbara ◽  
...  
Keyword(s):  
Acute Rejection ◽  
Collagen Type ◽  
Collagen Type Iv ◽  
Type Iv
Sign in / Sign up

Export Citation Format

Share Document